Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk Stock Rises
Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'
Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.
Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition
Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products
Novo Nordisk A/S (NYSE:NVO) Upgraded to Buy at UBS Group
Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a “buy” rating in a research note issued to investors on Wednesday,Benzinga reports.
Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone
UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed”
Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off "overdone"
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and is in pole position to benefit from strong near-term demand for new weight-loss drugs, according to analysts at UBS.
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from “Neutral” to “Buy.” Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes (T2D) and Wegovy injection for weight management.
bovnews
2m
Why Did Bernstein Give Novo Nordisk A/S (NVO) Stock Mkt Perform Rating?
Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $86.26 which represents a slight increase of $0.62 or 0.72% from the prior close of $85.64. The stock opened at $87.22 and touched a ...
Hosted on MSN
3d
Denmark's Novo Nordisk Rebounds Pre-Market On UBS Upgrade, But Trump's Tariff Threats Over Greenland Leaves Retail Uneasy
Novo Nordisk shares climbed over 3% in Wednesday's pre-market trading as U.S. stock futures rebounded from a tech-driven ...
1d
Deutsche Bank Sticks to Its Buy Rating for Novo Nordisk (0QIU)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
2d
European shares dip as bond yields jump on rate, tariff jitters
European shares dipped on Wednesday, as bond yields surged after investors priced in fewer interest rate cuts in Europe and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback